Bone health and therapeutic agents in advanced prostate cancer

Bone health and therapeutic agents in advanced prostate cancer

Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone lo...

Full description

Bibliographic Details
Main Authors:	Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost, Felipe Couñago
Format:	Article
Language:	English
Published:	IMR Press 2022-01-01
Series:	Frontiers in Bioscience-Landmark
Subjects:	bone health prostate cancer skeletal-related events osteoporosis denosumab bisphosphonates
Online Access:	https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701034

Similar Items

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
by: Christian Meier, et al.
Published: (2017-08-01)

Periapical status in patients affected by osteoporosis: A retrospective clinical study
by: Erika Cadoni, et al.
Published: (2022-10-01)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
by: Mark Clemons, et al.
Published: (2021-10-01)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
by: Alexander Stanoyevitch, et al.
Published: (2021-08-01)

Analysis of utilization of bisphosphonates, strontium ranelate and denosumabe in Serbia, Finland, Norway and Denmark in the period 2013-2016
by: Cvjetković Đurđa M., et al.
Published: (2019-01-01)

Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications
by: Kaleen N. Hayes, et al.
Published: (2024-03-01)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
by: Tetsuya Kaneko, et al.
Published: (2019-10-01)

The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?
by: Athanasios D. Anastasilakis, et al.
Published: (2021-03-01)

Osteogenesis imperfecta as a cause of death
by: Anastasia A. Malygina, et al.
Published: (2018-04-01)

Treatment of primary osteoporosis in men
by: Giusti A, et al.
Published: (2014-12-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice
by: Cheung AM, et al.
Published: (2016-09-01)

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
by: Peyman Hadji, et al.
Published: (2017-06-01)

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma
by: Petra Rugani, et al.
Published: (2016-09-01)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
by: Koki Tsuchiya, et al.
Published: (2021-06-01)

Antiresorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis
by: Nadezhda Y. Banshchikova, et al.
Published: (2018-12-01)

OSTEOPOROSIS AND JOINT REPLACEMENT
by: Holzer Gerold, et al.
Published: (2018-08-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01)

Basic and clinical associations between bone and cancer
by: Fang He, et al.
Published: (2020-07-01)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
by: Juan Erviti, et al.
Published: (2017-05-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
by: Enrique Casado, et al.
Published: (2022-01-01)

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool
by: Kamal Kant Sahu, et al.
Published: (2022-11-01)

Bone metastases: Are we failing our patients?
by: B. Tombal, et al.
Published: (2014-05-01)

Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases
by: Hoon-Je Chang, et al.
Published: (2023-02-01)

Use and risk of side effects of antiresorptive medication in people with intellectual disabilities [version 1; peer review: 2 approved]
by: Valeria Frighi, et al.
Published: (2022-12-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort
by: Cristina Mirelli, et al.
Published: (2022-05-01)

Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)

Bone metastases: an overview
by: Filipa Macedo, et al.
Published: (2017-05-01)

Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological Update
by: Gianluca Tenore, et al.
Published: (2014-12-01)

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
by: Heidi M. Ekholm, et al.
Published: (2021-08-01)

Comparison of the Effectiveness of Conservative and Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: a Systematic Review
by: Rial Seluki, et al.
Published: (2023-12-01)

Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman
by: E. Marasco, et al.
Published: (2021-04-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Impact of Monthly 120 Mg Denosumab on Bone Metabolism in Bone-metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Jimpei Miyakawa, et al.
Published: (2017-06-01)

Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review
by: Takashi Ohnishi, et al.
Published: (2021-04-01)

<i>ONJ (MRONJ) Update 2021</i>—Osteonecrosis of Jaw Related to Bisphosphonates and Other Drugs—Prevention, Diagnosis, Pharmacovigilance, Treatment: A 2021 Web Event
by: Vittorio Fusco, et al.
Published: (2022-04-01)